Skip to content

Evaluation of Ropivacaine, Liposomal Bupivacaine, and Liposomal Bupivacaine Combined with Dexamethasone for Postoperative Analgesia in Patients Undergoing Single-Port Video-Assisted Thoracoscopic Lobectomy

Evaluation of Ropivacaine, Liposomal Bupivacaine, and Liposomal Bupivacaine Combined with Dexamethasone for Postoperative Analgesia in Patients Undergoing Single-Port Video-Assisted Thoracoscopic Lobectomy: A Prospective, Randomized, Exploratory Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128406
Enrollment
Unknown
Registered
2026-07-20
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Liposomal bupivacaine group:Paravertebral nerve block with liposomal bupivacaine, with intravenous dexamethasone
Liposomal bupivacaine and dexamethasone combination group (Group LD ):Paravertebral nerve block with liposomal bupivacaine mixed with dexamethasone, with intravenous normal saline
Ropivacaine group (Group RP):Paravertebral nerve block with ropivacaine, with intravenous dexamethasone

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65, ASA I-III; 2. Patients planning to undergo single-port thoracoscopic-assisted lung cancer surgery under general anesthesia; 3. Agree to receive paravertebral nerve block and postoperative intravenous patient-controlled analgesia.

Exclusion criteria

Exclusion criteria: 1. Cases requiring conversion to open thoracotomy during surgery; 2. Contraindications to deep nerve block, including severe spinal deformity or history of spinal surgery, severe coagulation abnormalities (INR > 1.7, APTT exceeding the normal value by 4 seconds, platelet count 442 µmol/L or requiring renal replacement therapy), hepatic insufficiency (Child-Pugh Class C), or ASA classification >= IV; 4. Chronic opioid dependence and long-term use of various types of analgesics (for more than 3 months), such as those with chronic low back pain; 5. Inability to communicate due to severe dementia, language impairment, or terminal illness before surgery; 6. Recent use of antipsychotic medications; 7. Alcohol and/or drug abuse; 8. Known allergy to local anesthetics; 9. Expected need for postoperative tracheal intubation and admission to the ICU for further treatment; 10. Other conditions deemed by the attending physician or investigator to make the patient unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Postoperative 0–72 h Numerical Rating Scale (NRS) pain intensity score.;

Secondary

MeasureTime frame
opioid consumption;Cardiovascular stress indices (i.e., the area under the curve of heart rate/blood pressure changes over the 3 days postoperatively);

Countries

China

Contacts

Public ContactYanling Sun

Peking University First Hospital

lvv7307@163.com+86 10 8357 5085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026